A molecular basis for tetramer destabilization and aggregation of transthyretin Ala97Ser

Transthyretin (TTR)‐related amyloidosis (ATTR) is a syndrome of diseases characterized by the extracellular deposition of fibrillar materials containing TTR variants. Ala97Ser (A97S) is the major mutation reported in Taiwanese ATTR patients. Here, we combine atomic resolution structural information together with the biochemical data to demonstrate that substitution of polar Ser for a small hydrophobic side chain of Ala at residue 97 of TTR largely influences the local packing density of the FG‐loop, thus leading to the conformational instability of native tetramer, the increased monomeric species, and thus the enhanced amyloidogenicity of apo‐A97S. Based on calorimetric studies, the tetramer destabilization of A97S can be substantially altered by interacting with native stabilizers via similarly energetic patterns compared to that of wild‐type (WT) TTR; however, stabilizer binding partially rearranges the networks of hydrogen bonding in TTR variants while FG‐loops of tetrameric A97S still remain relatively flexible. Moreover, TTR in complexed with holo‐retinol binding protein 4 is slightly influenced by the structural and dynamic changes of FG‐loop caused by A97S substitution with an approximately five‐fold difference in binding affinity. Collectively, our findings suggest that the amyloidogenic A97S mutation destabilizes TTR by increasing the flexibility of the FG‐loop in the monomer, thus modulating the rate of amyloid fibrillization.

[1]  Salvador Ventura,et al.  Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity , 2016, Nature Communications.

[2]  A. Corazza,et al.  Calcium Binds to Transthyretin with Low Affinity , 2022, Biomolecules.

[3]  Y. Jeng,et al.  Unique Phenotypes With Corresponding Pathology in Late-Onset Hereditary Transthyretin Amyloidosis of A97S vs. V30M , 2022, Frontiers in Aging Neuroscience.

[4]  E. Papaleo,et al.  Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation , 2021, The Journal of biological chemistry.

[5]  S. Gottlieb,et al.  Characteristics of Patients with Late- vs. Early-Onset Val30Met Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS) , 2021, Neurology and Therapy.

[6]  Y. Vorasettakarnkij,et al.  Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort , 2021, BMC Neurology.

[7]  H. Lv,et al.  Hereditary transthyretin amyloidosis in mainland China: a unicentric retrospective study , 2021, Annals of clinical and translational neurology.

[8]  M. Schupp,et al.  Biological Functions of RBP4 and Its Relevance for Human Diseases , 2021, Frontiers in Physiology.

[9]  L. Lopiano,et al.  Safety and efficacy of tolcapone in Parkinson’s disease: systematic review , 2021, European Journal of Clinical Pharmacology.

[10]  M. Saraiva,et al.  Modulation of the Mechanisms Driving Transthyretin Amyloidosis , 2020, Frontiers in Molecular Neuroscience.

[11]  S. Kędracka-Krok,et al.  Destabilisation of the structure of transthyretin is driven by Ca2. , 2020, International journal of biological macromolecules.

[12]  M. Mizuguchi,et al.  Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments. , 2020, Journal of medicinal chemistry.

[13]  R. Griffin,et al.  Disruption of the CD loop by Enzymatic Cleavage Promotes the Formation of Toxic Transthyretin Oligomers through a Common Transthyretin Misfolding Pathway. , 2020, Biochemistry.

[14]  A. Velázquez‐Campoy,et al.  Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis , 2020, The FEBS journal.

[15]  C. Sommer,et al.  Amyloidosis-the Diagnosis and Treatment of an Underdiagnosed Disease. , 2020, Deutsches Arzteblatt international.

[16]  A. Pelayo-Negro,et al.  Overview of treatments used in transthyretin-related hereditary amyloidosis: a systematic review. , 2019, European journal of hospital pharmacy : science and practice.

[17]  K. Chien,et al.  Cardiac manifestations and prognostic implications of hereditary transthyretin amyloidosis associated with transthyretin Ala97Ser. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.

[18]  Chih-Chiang Chan,et al.  Cellular secretion and cytotoxicity of transthyretin mutant proteins underlie late-onset amyloidosis and neurodegeneration , 2019, Cellular and Molecular Life Sciences.

[19]  M. Waddington‐Cruz,et al.  Late-onset hereditary ATTR V30M amyloidosis with polyneuropathy: Characterization of Brazilian subjects from the THAOS registry , 2019, Journal of the Neurological Sciences.

[20]  M. Slama,et al.  Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease , 2019, Nature Reviews Neurology.

[21]  Yi-Chung Lee,et al.  Clinical and genetic profiles of hereditary transthyretin amyloidosis in Taiwan , 2019, Annals of clinical and translational neurology.

[22]  Whei-Min Lin,et al.  Skin nerve pathology: Biomarkers of premanifest and manifest amyloid neuropathy , 2019, Annals of neurology.

[23]  Yanguo Xin,et al.  Tafamidis, a Noninvasive Therapy for Delaying Transthyretin Familial Amyloid Polyneuropathy: Systematic Review and Meta-Analysis , 2018, Journal of clinical neurology.

[24]  S. Hsieh,et al.  Sensory nerve degeneration in a mouse model mimicking early manifestations of familial amyloid polyneuropathy due to transthyretin Ala97Ser , 2018, Neuropathology and applied neurobiology.

[25]  H. Dyson,et al.  NMR Measurements Reveal the Structural Basis of Transthyretin Destabilization by Pathogenic Mutations. , 2018, Biochemistry.

[26]  O. Gursky,et al.  Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease , 2018, Proceedings of the National Academy of Sciences.

[27]  J. Hsu,et al.  Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis. , 2018, Journal of visualized experiments : JoVE.

[28]  D. Adams,et al.  Familial amyloid polyneuropathy , 2017, Current opinion in neurology.

[29]  M. de Carvalho,et al.  Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation , 2017, Scientific Reports.

[30]  C. Chao,et al.  The Temporal Profiles of Changes in Nerve Excitability Indices in Familial Amyloid Polyneuropathy , 2015, PloS one.

[31]  D. Hirschberg,et al.  Considerably Unfolded Transthyretin Monomers Preceed and Exchange with Dynamically Structured Amyloid Protofibrils , 2015, Scientific Reports.

[32]  Lei Z. Robinson,et al.  Quantification of Quaternary Structure Stability in Aggregation-Prone Proteins under Physiological Conditions: The Transthyretin Case , 2014, Biochemistry.

[33]  C. Robinson,et al.  Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis , 2014, Proceedings of the National Academy of Sciences.

[34]  E. Nordh,et al.  Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. , 2013, JAMA.

[35]  I. Graef,et al.  AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin , 2013, Proceedings of the National Academy of Sciences.

[36]  I. Merkies Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial , 2013, Neurology.

[37]  H. Dyson,et al.  Localized structural fluctuations promote amyloidogenic conformations in transthyretin. , 2013, Journal of molecular biology.

[38]  M. Saraiva,et al.  Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin , 2012, FEBS letters.

[39]  S. Hsieh Amyloid neuropathy with transthyretin mutations: overview and unique Ala97Ser in Taiwan. , 2011, Acta neurologica Taiwanica.

[40]  L. Cendron,et al.  Structural and mutational analyses of protein–protein interactions between transthyretin and retinol‐binding protein , 2008, The FEBS journal.

[41]  Yi-Chung Lee,et al.  Transthyretin Ala97Ser in Chinese–Taiwanese patients with familial amyloid polyneuropathy: Genetic studies and phenotype expression , 2008, Journal of the Neurological Sciences.

[42]  Steven M. Johnson,et al.  Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. , 2008, Journal of medicinal chemistry.

[43]  C. Waters,et al.  Role of tolcapone in the treatment of Parkinson’s disease , 2007, Expert review of neurotherapeutics.

[44]  K. Henrick,et al.  Inference of macromolecular assemblies from crystalline state. , 2007, Journal of molecular biology.

[45]  T. Aizawa,et al.  Destabilization of transthyretin by pathogenic mutations in the DE loop , 2006, Proteins.

[46]  J. Kelly,et al.  R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression , 2006, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[47]  Steven M. Johnson,et al.  Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. , 2005, Accounts of chemical research.

[48]  J. Kelly,et al.  Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[49]  James C Sacchettini,et al.  Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. , 2004, Journal of medicinal chemistry.

[50]  G. Zanotti,et al.  Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin. , 2004, Vitamins and hormones.

[51]  O. Suhr Impact of liver transplantation on familial amyloidotic polyneuropathy (FAP) patients' symptoms and complications , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[52]  M. Lei,et al.  Why is Leu55→Pro55 transthyretin variant the most amyloidogenic: Insights from molecular dynamics simulations of transthyretin monomers , 2003, Protein science : a publication of the Protein Society.

[53]  T. Tokuda,et al.  Energetic Characteristics of the New Transthyretin Variant A25T May Explain Its Atypical Central Nervous System Pathology , 2003, Laboratory Investigation.

[54]  J. Kelly,et al.  Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[55]  J. Kelly,et al.  The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Kelly,et al.  Support for the multigenic hypothesis of amyloidosis: The binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[57]  A. Olofsson,et al.  A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. , 2000, Journal of molecular biology.

[58]  D. Booth,et al.  Transthyretin Ala97Ser is associated with familial amyloidotic polyneuropathy in a Chinese‐Taiwanese family , 2000, Human mutation.

[59]  H. Ideta,et al.  A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. , 1999, Biochemical and biophysical research communications.

[60]  C. Wurth,et al.  The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. , 1999, Biochemistry.

[61]  J. Kelly,et al.  Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. , 1998, Biochemistry.

[62]  J. Kelly,et al.  Recombinant human retinol-binding protein refolding, native disulfide formation, and characterization. , 1998, Protein expression and purification.

[63]  J. Kelly,et al.  The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. , 1996, Biochemistry.

[64]  P. Argos,et al.  Knowledge‐based protein secondary structure assignment , 1995, Proteins.

[65]  A Coda,et al.  Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. , 1995, Science.

[66]  J. Phang,et al.  Production of human plasma retinol-binding protein in Escherichia coli. , 1993, Gene.

[67]  J. Hamilton,et al.  The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30-->Met variant to 1.7-A resolution. , 1993, The Journal of biological chemistry.

[68]  P. Albertsson,et al.  Interaction between prealbumin and retinol-binding protein studied by affinity chromatography, gel filtration and two-phase partition. , 1979, European journal of biochemistry.

[69]  P. A. Peterson,et al.  Studies on thyroid hormone-binding proteins. II. Binding of thyroid hormones, retinol-binding protein, and fluorescent probes to prealbumin and effects of thyroxine on prealbumin subunit self association. , 1975, The Journal of biological chemistry.

[70]  Howard C. Berg,et al.  Genetic analysis , 1957, Nature Biotechnology.